Skip to main content
Equibles
GLUE logo

GLUE · Monte Rosa Therapeutics, Inc. · Webcasts, Transcripts & Audio

Track GLUE — free

Use GLUE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GLUE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$10.40 +0.13 (+1.27%)
Russell 2000 member Rebalance outlook locked
Market Cap
$1.00B
Shares
85.31M
Volume · Oct 5 1.75M Avg daily vol (3M) 1.31M

Monte Rosa Therapeutics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Monte Rosa Therapeutics, Inc. (GLUE), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $ −$33.25M '23 Q4 24-03-14 · $9.22M −$23.86M '24 Q3 24-11-07 · $60.65M $13.44M '24 Q4 25-03-20 LATEST ▼95.4% $2.78M −$46.11M '25 Q4 26-01-07
Investor Update
Investor event
2026-02-26
Monte Rosa Therapeutics, Inc. (GLUE) February 2026 Investor Update
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-01-07
Monte Rosa Therapeutics, Inc. (GLUE) Q4 2025 Earnings Call
Revenue
$2.78M*
▼ 95.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q4
2025-03-20
Monte Rosa Therapeutics, Inc. (GLUE) Q4 2024 Earnings Call Transcript
Confident tone MRT-6160 / VAV1 Phase 1 results NEK7 program Pipeline breadth in I&I
Revenue
$60.65M*
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Monte Rosa Therapeutics, Inc. (GLUE) Q3 2024 Earnings Call
Revenue
$9.22M
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-14
Monte Rosa Therapeutics, Inc. (GLUE) Q4 2023 Earnings Call
Revenue
$*
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q4
2023-03-16
Monte Rosa Therapeutics, Inc. (GLUE) Q4 2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–6 of 6 webcasts
Key facts CIK 1826457 CUSIP 61225M102 13F (30d) 2 filings 2 filers Visit website Investor relations